Drugs & Targets FDA grants Breakthrough Therapy designation for daraxonrasib in pancreatic cancer June 27, 2025Vol.51 No.25
Trials & Tribulations Optimizing dosing of expensive and toxic oncology drugs: Making America healthier June 20, 2025Vol.51 No.24By Mark J. Ratain, David A. Hyman, Jill E. Feldman, Beth R. Jacobson and Allen S. Lichter
Cancer Policy FDA to issue “national priority vouchers” to companies supporting U.S. interests June 20, 2025Vol.51 No.24By Claire Marie Porter
Cancer Policy Vinay Prasad named chief medical and scientific officer at FDA June 20, 2025Vol.51 No.24By Claire Marie Porter
Cancer Policy FDA halts new clinical trials that export Americans’ cells to foreign labs in hostile countries June 20, 2025Vol.51 No.24By Claire Marie Porter
Clinical Roundup Talvey + Tecvayli show deep and durable responses in heavily pretreated MM patients with extramedullary disease June 20, 2025Vol.51 No.24
Drugs & Targets FDA approves Zusduri for intravesical solution in recurrent LG-IR-NMIBC June 20, 2025Vol.51 No.24
Cancer Policy Kennedy: “We’re going to end the war at FDA against alternative medicine” June 13, 2025Vol.51 No.23By Jacquelyn Cobb
Drugs & Targets FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC June 13, 2025Vol.51 No.23
